ArticleJournal of Korean medical science2025
Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Efficacy and Safety of Inhaled Maintenance Therapy Strategies for Quality of Life in COPD: A Systematic Review and Bayesian Network Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Pyroptosis in chronic obstructive pulmonary disease: Beyond the canonical NLRP3/Caspase-1/GSDMD pathway.Immunologic research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough the efficacy of triple therapy in treating chronic obstructive pulmonary disease (COPD) patients with a history of exacerbation is well established in groups with frequent exacerbations, less research has been conducted on its use in group B. Here, we investigated the effects of triple therapy on COPD patients with low eosinophil counts in the context of the current management of group B.
methodsUsing data from the Korean COPD Subtype Study (KOCOSS), we selected patients with blood eosinophil count (BEC) less than 300 cells/μL as non-eosinophilic COPD groups. The study evaluated the effect of a triple therapy group (combination of inhaled corticosteroid, a long-acting β2-agonist [LABA] and a long-acting muscarinic antagonist [LAMA]) and a dual therapy group (LABA/LAMA) on moderate-to-severe exacerbations, as well as longitudinal changes in lung function over 3 years in patients categorized as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B.
resultsOf the 328 non-eosinophilic COPD group B, 145 (44.2%) patients were in triple therapy and 183 (55.8%) patients were in dual therapy. Triple therapy group showed an increased risk of moderate-to-severe exacerbation in multivariate adjusted model (adjusted incidence rate ratio of annual rate, 2.04; 95% confidence interval, 1.45 to 2.84;
conclusionIn conclusion, our research suggests that triple therapy was associated with a higher risk of moderate-to-severe exacerbations in non-eosinophilic COPD categorized as GOLD B compared with dual therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.